Targets › CDKN1A
1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout May 2027.
Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. (UniProt, P38936)
Open in Phaseline: the race on CDKN1A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| UNICANCER | HIPEC (Hyperthermic Intra-Peritoneal Chemotherapy with cisplatin) Hyperthermic intra-peritoneal chemotherapy delivering cisplatin directly to peritoneal cav | CDKN1A | Phase 3 | Ovarian Epithelial Cancer Recurrent | May 2027 |
Ovarian Epithelial Cancer Recurrent (1)
small molecule (1)
UNICANCER (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.